Medios AG / Key word(s): Preliminary Results
15-Feb-2017 / 10:28 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Medios AG reports an increase in revenue and profit for fiscal year 2016
Berlin, February 15, 2017 - Medios AG, an expert pharmaceutical partner and
solution provider in the Specialty Pharma segment, announces that its two
subsidiary companies have developed very positively in the 2016 fiscal
year. According to provisional figures (IFRS), Medios Pharma GmbH and
Medios Manufaktur GmbH experienced a significant increase in revenues and
profit compared to the previous year:
Medios Pharma GmbH
- Sales revenue increased by 119% to EUR 127.5 m (prior year EUR 58.2 m)
- EBIT* increased by 268% to EUR 3.92 m (prior year EUR 1.06 m)
Medios Manufaktur GmbH
- Sales revenue increased by 23% to EUR 43.5 m (prior year EUR 35.3 m)
- EBIT* increased by 16.5% to EUR 2.34 m (prior year EUR 2 m)
Because both subsidiaries are to be consolidated only for the period of
time after the contribution due to the contribution occurring during the
course of the year in accordance with IFRS, the management board is
additionally providing provisional pro forma figures (IFRS) for fiscal year
2016 for the purpose of comparisons. According to this information, Medios
AG recorded an increase in revenue and profit compared to the prior year:
- Consolidated sales revenue pro forma increased by 78% to EUR 160.5 m
(prior year EUR 90.1 m**)
- Consolidated EBIT* pro forma increased by 100.4% to EUR 5.67 m (prior
year EUR 2.83 m**)
The provisional IFRS results for the 2016 consolidated annual financial
statements are not yet available.
* EBIT is defined as the earnings before income tax minus interest income
plus interest expense
** According to securities prospectus of November 16, 2016
Medios AG
Matthias Gärtner, board member
About Medios AG
Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios
Manufaktur GmbH, has positioned itself in the specialty pharma segment as
the go-to source for expertise and solutions. It brings together individual
market players in a network of cooperating partners. Our objective is to
ensure that patients have optimum access to pharmaceutical drugs and to
offer integrated solutions along the value-added chain to partners and
customers. Specialty pharmaceutical drugs are medications for patients with
rare and/or chronic illnesses (for example, certain cancer, autoimmune
diseases, and infectious diseases) that require lengthy and expensive
customised treatment.
Contact
Medios AG
Matthias Gärtner
Friedrichstraße 113a
10117 Berlin
Phone: +49 30 232 5668 0
Fax: +49 30 232 5668 66
E-Mail: ir@medios.ag
www.medios.ag
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the forward-
looking statements contained in this notification.
15-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of Announcement DGAP News Service